University of Utah startups continue innovating and discovering solutions to today’s unmet needs. Here’s a roundup of some of the latest news out of these companies:
Carterra unveils its most sensitive biosensor platform; Carterra Ultra™ ushers in a new frontier in fragment and small molecule drug discovery
Carterra Inc., the world leader in innovative technologies enabling high-throughput biology, has launched Carterra Ultra™—the latest addition to its LSA® and LSAXT label-free high-throughput surface plasmon resonance (HT-SPR) instruments. The Ultra platform enables small molecule applications with the same high throughput, rapid data collection, and low sample volume as Carterra’s first two systems while also delivering the utmost sensitivity to characterize molecules as small as 100 Daltons.
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced top-line results of the SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for REC-994 in symptomatic CCM patients.
